Bronchodilatation Effects of a Small Volume Spacer Used With a Metered-Dose Inhaler (MDI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00465413|
Recruitment Status : Completed
First Posted : April 25, 2007
Last Update Posted : November 14, 2007
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Device: Small volume spacer and/or Rinsing the mouth with water||Phase 2|
Administration of bronchodilator drugs with metered-dose inhalers (MDIs) is difficult for some patients because the timing of the spray and the inhalation must be coordinated exactly. Use of spacers seems to improve delivery in these patients. It is not clear, however, if there is any advantage to a spacer for patients who are able to use an MDI with correct technique.
The purpose of the present study is to determine whether use of a small volume spacer is associated with better bronchodilatation in an unselected population of patients with documented reversible airflow limitations. The intervention in the first part of the study is use of an MDI with or without a spacer to deliver a bronchodilator (2 puffs, 0.4 mg of fenoterol). Spirometry is performed before and after the inhalation.
The second part of the study is conducted identically to the first with the same conditions and variables but with the addition of rinsing the mouth with 100 mL of water after inhaling the bronchodilator but before the second spirometry measurement.
The outcome to be measured is the increase in forced expiratory volume in 1 second (FEV1) and forced expiratory flow rate (FEF25-75%).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||September 2004|
- forced expiratory volume in 1 second (FEV1)
- forced expiratory flow rate (FEF25-75%)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00465413
|Mackay Memorial Tamshui Branch Hospital|
|Tamshui, Taipei, Taiwan, 25115|
|Mackay Memorial Taitung Branch Hospital|
|Taitung, Taiwan, 95017|
|Study Chair:||Ching-Lung Liu, MD||Mackay Memorial Taitung Branch Hospital|
|Principal Investigator:||Yen-Ta Lu, MD, PhD.||Mackay Memorial Tamshui Branch Hospital|